MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Pharmacotherapy"

  • 2023 International Congress

    Understanding patient perceptions of advanced Parkinson’s disease (aPD) treatments

    J. Domingos, R. Pahwa, A. Antonini, I. Malaty, S. Lindvall, F. de Renzis, C. Yan, K. Pantiri, N. Touba, E. Evans, A. Alobaidi, A. Shewale, M. Shah, P. Kukreja, J. Zamudio, K. Chaudhuri (Orpington Kent, United Kingdom)

    Objective: To explore patients’ perceptions of treatment options for aPD and treatment decision considerations. Background: As PD advances, some people with Parkinson’s (PwP) on oral…
  • 2023 International Congress

    Alopecia in females with young onset Parkinson’s Disease: an exploratory survey

    K. Fisher, E. Clifford, N. Piniella, A. Leder, R. Gallagher (Glen Head, USA)

    Objective: To explore the symptoms of females with young onset Parkinson's Disease (YOPD), specifically alopecia, in comparison to females with traditional onset Parkinson’s Disease (TOPD).…
  • 2023 International Congress

    The mGlu2 positive allosteric modulator AZD8529 alleviates L-DOPA-induced dyskinesia and psychosis-like behaviours in the parkinsonian marmoset

    J. Shaqfah, I. Frouni, C. Kwan, D. Bédard, S. Nuara, J. Gourdon, A. Hamadjida, P. Huot (Montreal, Canada)

    Objective: To assess the effect of the metabotropic glutamate 2 (mGlu2) receptor positive allosteric modulator (PAM) AZD8529 on L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia and psychosis-like behaviours (PLBs)…
  • 2023 International Congress

    Clinical analysis of Levodopa/carbidopa intestinal gel infusion in advanced Parkinson’s disease. A single-center retrospective cohort study.

    D. Rivero Rodriguez, G. Tabar Comellas, MI. Morales Casado, AM. Diezma Martin, D. Garcia Melendez, M. Ennazeh Elkhaili, N. López Ariztegui (Toledo, Spain)

    Objective: To evaluate clinical impact of treatment (LCIG) infusion in patients with advanced PD. Background: Levodopa/carbidopa intestinal gel (LCIG) infusion has demonstrated more stable plasma…
  • 2023 International Congress

    Integrated analysis of phase 3 trials of foslevodopa/foscarbidopa demonstrated that majority of reported infusion site AEs including infections were non serious, mild to moderate in severity and did not result in treatment discontinuation.

    P. Odin, T. Kimber, B. Bergmans, E. Freire-Alvarez, F. Gandor, S. Isaacson, S. Dhanani, R. Hauser, M. O'Meara, A. Jeong, J. Jia, R. Gupta, L. Bergmann, M. Shah, L. Harmer, S. Talapala, J. Aldred (Lund, Sweden)

    Objective: To characterize reported infusion site infection adverse events (AEs) and their clinical management in patients with Parkinson’s disease (PD) treated with foslevodopa/foscarbidopa (LDP/CDP). Background:…
  • 2023 International Congress

    Pharmacological combinations in early stages of Parkinson’s disease and association with motor complications

    A. Lanore, E. Januel, N. Bertille, P. Menon, Y. Rajasegaram, S. Carvalho, LL. Mariani, M. Fabbri, O. Rascol, F. Tubach, Y. de Rycke, JC. Corvol (Paris, France)

    Objective: To describe the different combinations of dopaminergic drugs at the early stage of Parkinson’s disease (PD) in a real-life cohort, and to determine their…
  • 2023 International Congress

    Quetiapine for the treatment of psychosis in dementia with Lewy bodies: a systematic review.

    M. Giusti, PL. Silva, G. Bolner, C. Menegon, MF. Felippe, G. Herwig, A. Rossato, EG. Almeida, M. Rosa, CR. Rieder (Porto Alegre, Brazil)

    Objective: Perform a systematic review of the literature about the efficacy of quetiapine in the treatment of psychosis in patients with Lewy’s Body Dementia. Background:…
  • 2023 International Congress

    Bowel symptoms and management practices in Parkinson’s disease and related conditions: results from the PRIME-UK study.

    C. Thomas, E. Tenison, K. Lloyd, M. Smith, Y. Ben-Shlomo, E. Henderson (Gloucestershire, United Kingdom)

    Objective: To describe bowel symptoms and constipation management practices in a large, representative cross-sectional study of Parkinson’s and related disorders. Background: Bowel symptoms, particularly constipation,…
  • 2022 International Congress

    Chronic administration of bitopertin, a GlyT1 inhibitor, in the dyskinetic 6-OHDA-lesioned rat model of Parkinson’s disease

    I. Frouni, W. Kang, D. Bédard, L. Desbiens, C. Kwan, A. Hamadjida, P. Huot (Montreal, Canada)

    Objective: To evaluate if, upon chronic administration, tolerance to the anti-dyskinetic effect of the glycine transporter 1 (GlyT1) inhibitor bitopertin, would develop, in the 6-hydroxydopamine…
  • 2022 International Congress

    Systematic Literature Review of Key Outcomes Used to Assess Adjunctive Treatments for Parkinson’s Disease

    A. Thach, M. Zichlin, M. Peddle, M. Du, A. Lerner, N. Kirson, A. Bowling, D. Mehta, R. Williams (Marlborough, USA)

    Objective: Understand key efficacy outcomes used to assess adjunctive treatments to carbidopa/levodopa (CD/LD) for Parkinson’s disease (PD). Background: CD/LD is widely considered the most effective…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 34
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #24970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley